Insider Brief
- AcuityMD, an AI platform for MedTech, raised $80 million in Series C funding led by StepStone Group, with participation from Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management, bringing total funding to over $160 million and valuing the company at $955 million.
- The platform aggregates data from claims databases, FDA filings, government records, and market signals into a proprietary MedTech knowledge graph, aligning it with each customer’s internal data to give commercial teams a unified, continuously updated view of the healthcare market — and now serves 16 of the top 20 MedTech companies.
- New capital will be used to accelerate agentic AI capabilities for sales and marketing teams, deepen its MedTech data model, and expand the platform beyond commercial use cases across the full product lifecycle.
PRESS RELEASE — AcuityMD, the AI platform for MedTech, announced $80 million in new funding to elevate its platform with advanced artificial intelligence (AI) capabilities and drive the company’s mission of accelerating adoption of medical technology. The Series C round was led by existing investor StepStone Group, with additional participation from Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management. Now supporting 16 of the top 20 MedTech companies and having helped customers identify over $34 billion in pipeline, AcuityMD has raised more than $160 million to date and is valued at $955 million.
“AcuityMD is scaling rapidly while continuing to invest thoughtfully in its people and platform,” said Hunter Somerville, Partner at StepStone Group. “The depth of the company’s data provides a meaningful advantage, and as AI capabilities continue to advance, that foundation becomes more valuable. We also see significant opportunities for AcuityMD to benefit the broader MedTech organization beyond commercial, reinforcing our decision to deepen our commitment.”
MedTech companies face mounting pressure not only to successfully launch innovations, but also to capture and grow market share in an environment that can shift abruptly. Portfolio changes, hospital consolidation, regulatory fluctuation, and reimbursement updates can upend the competitive landscape faster than any sales representative or leader can track on their own.
AcuityMD was built to solve the root cause of the problem: the commercial insights MedTech companies need are scattered across claims databases, FDA filings, government records, and market signals that no single MedTech company can assemble alone. AcuityMD aggregates all of it into a proprietary MedTech ontology: a continuously enriched knowledge graph mapping entities including physicians, facilities, networks, procedures, reimbursement dynamics, and the relationships between them. It aligns that ontology with each customer’s internal data, including contracting information, product indications, territory structure, and CRM activity. The result is a unified, always updated view of the healthcare market for faster, smarter commercial execution.
AcuityAI, now available in open beta, is the AI built on that foundation. It connects AcuityMD’s ontology, a company’s business context, and each rep’s specific situation to surface answers no horizontal AI platform can replicate. Reps spend less time figuring out where to go and more time in front of the right physicians, armed with the right context to win more business.
“AcuityAI has given our commercial team sharper answers, faster,” said Mark Edwards, senior director of sales operations at Kuros Biosciences. “Insights that used to take hours are now surfaced right when our reps need them, leading to richer conversations and opportunities we might otherwise have missed. One of our sales leaders asked AcuityAI for intel on a new national contract with a large health system, and quickly had a full business plan: where to go, which surgeons to prioritize, and more context than he could get spending hours on Google.”
AcuityMD’s new capital will fund three priorities: accelerate agentic AI capabilities for commercial personas, including sales reps, leadership and marketing teams; deepen the MedTech ontology that powers AcuityMD’s data model; and expand the platform beyond commercial in pursuit of the company’s broader mission to accelerate the adoption of medical technology across the full product lifecycle.
“AI will transform MedTech, but only with the right context, deeply embedded in the workflows where decisions are made. AcuityMD is that context layer, serving the rep in the field, the commercial leader planning territories, and the teams launching the next generation of innovation. I’m grateful to the hundreds of customers who have helped shape our platform,” concluded Mike Monovoukas, CEO and co-founder of AcuityMD. “This funding accelerates our shared mission of accelerating adoption of cutting-edge medical technologies.”
About AcuityMD
AcuityMD is the AI platform for MedTech trusted by over 400 MedTech companies — including 16 of the top 20. Commercial teams use AcuityMD to identify target markets, surface top opportunities, and grow their business. By combining real-world healthcare data with AI-powered insights, AcuityMD enables companies from pre-commercial to enterprise to understand where and how to sell faster to accelerate the adoption of medical technology. AcuityMD was named to Forbes’ 2025 “Next Billion-Dollar Startups” list — an elite group of 25 venture-backed U.S. companies identified as most likely to reach a $1 billion valuation.
Contacts
Media Contact:
Lisa Barbadora, Barbadora INK for AcuityMD
+1 (610) 420–3413
lbarbadora@barbadoraink.com
